Señales en vivo de MRSN | Maximiza tus Ganancias con Getagraph.com

COMPRAR 110418 min ago

@ $3.79

Emitido: 14 feb 2024 @ 13:46

Retorno: -16.36%

Señal anterior: feb 14 - 09:30

Señal anterior: Vender

Retorno: -3.33 %

Live Chart Being Loaded With Signals

Commentary (30 abr 2024 @ 16:00):

Stats
Volumen de hoy	1.16M
Volumen promedio	2.23M
Capitalización de mercado	382.24M
EPS	$0 ( 2024-02-27 )
Próxima fecha de ganancias	( $-0.180 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.800
ATR14	$0.00800 (0.25%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Alleva Lawrence M	Buy	3 996	Stock Option (right to buy)
2024-01-13	Mandelia Ashish	Buy	0
2024-01-15	Protopapas Anna	Buy	17 708	Common Stock
2024-01-15	Protopapas Anna	Buy	21 250	Common Stock
2024-01-16	Protopapas Anna	Sell	29 399	Common Stock

INSIDER POWER
74.95
Last 98 transactions
Buy: 4 017 838 \| Sell: 585 969

Volumen Correlación

Largo: -0.35 (neutral)

Corto: 0.28 (neutral)

Signal:(47.61) Neutral

Mersana Therapeutics Inc Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mersana Therapeutics Inc Correlación - Moneda/Commodity

-0.34
( neutral )

-0.63
( weak negative )

-0.66
( moderate negative )

-0.62
( weak negative )

0.25
( neutral )

Mersana Therapeutics Inc Finanzas

Annual	2023
Ingresos:	$36.86M
Beneficio Bruto:	$35.34M (95.88 %)
EPS:	$-1.480

FY	2023
Ingresos:	$36.86M
Beneficio Bruto:	$35.34M (95.88 %)
EPS:	$-1.480

FY	2022
Ingresos:	$26.58M
Beneficio Bruto:	$25.65M (96.51 %)
EPS:	$-2.22

FY	2021
Ingresos:	$43 000.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-2.37

Financial Reports:

No articles found.

Mersana Therapeutics Inc

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.